Loading...
•
Sep 26, 2020
Hologic Q4 2020 Earnings Report
Hologic's Q4 2020 financial performance was driven by strong sales of COVID tests, resulting in a 55.6% increase in revenue and GAAP diluted EPS of $1.88.
Key Takeaways
Hologic, Inc. reported strong financial results for the fourth quarter of fiscal year 2020, with revenue increasing by 55.6% to $1.347 billion. The company's performance was driven by strong sales of COVID-19 tests, which offset declines in other businesses. GAAP diluted EPS was $1.88, and non-GAAP diluted EPS was $2.07.
Revenue increased 55.6% for the quarter, or 54.2% in constant currency.
Organic revenue in the fourth quarter increased 72.5%, or 70.9% in constant currency.
GAAP earnings per share (EPS) were $1.88, compared to ($0.46) in the prior year period.
Non-GAAP EPS of $2.07 increased 218.5% over the prior year period.
Hologic
Hologic
Hologic Revenue by Segment
Hologic Revenue by Geographic Location
Revenue by Segment
Diagnostics Revenue
CapyFin.comMolecular Diagnostics Revenue
CapyFin.comBlood Screening Revenue
CapyFin.comBreast Health Revenue
CapyFin.comBreast Imaging Revenue
CapyFin.comInterventional Breast Solutions Revenue
CapyFin.comGYN Surgical Revenue
CapyFin.comSkeletal Health Revenue
CapyFin.comRevenue by Geographic Location
International Revenue
CapyFin.com Forward Guidance
Hologic expects strong financial performance to continue in the first quarter of fiscal 2021, driven by COVID tests and continued recovery of other businesses.
Positive Outlook
- Revenue between $1.35 billion and $1.425 billion
- Reported revenue increase of 58.7% to 67.6%
- Constant currency revenue increase of 56.6% - 65.4%
- Organic revenue increase of 71.1% - 80.8%
- Non-gaap EPS between $2.10 and $2.25
Revenue & Expenses
Visualization of income flow from segment revenue to net income